Reports Q4 revenue $3.17B, consensus $3.13B. “In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time. We aim to demonstrate that our vision for Kodiak 2.0 as a precommercial stage retina focused biotech company with a maturing portfolio of three promising Phase 3 assets on track for topline data in 2026 is well-supported by our science and our progress on execution,” said Victor Perlroth, M.D., Chairman and Chief Executive Officer of Kodiak Sciences.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXC:
- Options Volatility and Implied Earnings Moves Today, May 14, 2025
- DXC Technology collaborates with Microsoft and SAP to launch SXC Complete
- DXC Technology price target lowered to $16 from $23 at Susquehanna
- DXC Technology appoints Anders Lange as Chief Procurement Officer
- DXC Technology appoints T.R. Newcomb as Chief Revenue Officer